Search - tctmd.com

Displaying 261 - 280 of 542

Sort: Relevancy | Date

News Conference News TCT 2017

MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months

TCT Daily Staff

November 06, 2017

News Conference News TCT 2017

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

L.A. McKeown

November 02, 2017

News Conference News TCT 2017

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

Todd Neale

November 02, 2017

News Conference News TCT 2017

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Yael L. Maxwell

November 02, 2017

News Conference News TCT 2017

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

Todd Neale

November 01, 2017

News Conference News TCT 2017

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Michael O'Riordan

November 01, 2017

Presentation TCT 2017

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Jacek Legutko

November 01, 2017

Presentation TCT 2017

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

Presenter: Sanjay Kaul, Tullio Palmerini, Evald H. Christiansen

November 01, 2017

News Conference News TCT 2017

RECAP: In the Cath Lab, a Lead-free Pad Placed on the Patient Cuts Operator Radiation Exposure

Todd Neale

November 01, 2017

News Conference News TCT 2017

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Yael L. Maxwell

November 01, 2017

News Opinion Editor's Corner TCT 2017

Live From Denver: TCT 2017, Day Three

Shelley Wood

November 01, 2017

News Conference News TCT 2017

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Yael L. Maxwell

October 31, 2017

News Conference News TCT 2017

Long-term Absorb BVS Data Continue to Disappoint

Michael O'Riordan

October 31, 2017

News Conference News TCT 2017

Live From Denver: TCT 2017, Day Two

Shelley Wood

October 31, 2017

Presentation TCT 2017

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

Presenter: Nick Curzen, Rod H. Stables

October 31, 2017

Presentation TCT 2017

The NOTION 2 Low-risk Trial in Younger Patients

Presenter: Lars Sondergaard

October 30, 2017

Presentation TCT 2017

The Evolut R Low-risk Trial

Presenter: Jeffrey J. Popma

October 30, 2017

Presentation TCT 2017

The PARTNER 3 Low-risk Trial

Presenter: Michael J. Mack

October 30, 2017

Presentation TCT 2017

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Presenter: Thomas Walther

October 30, 2017

Presentation TCT 2017

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Presenter: Michael J. Reardon

October 30, 2017

Advertisement

MAVERIC: Transcatheter MV Repair Shows Continued Efficacy, Safety at 6 Months

FAME 2 at 3 Years: Outcomes, Symptoms Better With PCI vs OMT in Stable CAD, at Similar Cost

Longer-term Outcomes of Watchman Reassure as Debate Continues Over How It Should Be Used

For ‘Torrential’ Tricuspid Regurgitation, Two New Transcatheter Devices Safe, Effective in Early Results

Shortened DAPT Durations Appear Safe for Patients With ACS Implanted With DES

DES With Bioresorbable Polymer Outperforms BMS in SENIOR Patients

Flash Debate: If Anything, Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should be Downgraded Based on EXCEL and NOBLE!

Flash Debate: Guideline Recommendations for PCI in Low-to-Intermediate Risk Left Main Disease Should Be Upgraded to Class I Based on EXCEL and NOBLE!

RECAP: In the Cath Lab, a Lead-free Pad Placed on the Patient Cuts Operator Radiation Exposure

TRACER: Novel Device Effective in Reducing Severe Degenerative MR Over 6 Months

Live From Denver: TCT 2017, Day Three

Intermediate-Risk TAVR Substantially More Cost-effective Than Surgery

Long-term Absorb BVS Data Continue to Disappoint

Live From Denver: TCT 2017, Day Two

Case #1 Introduction: Low-Risk 65-Year-Old Patient With Severe Aortic Stenosis Refuses Surgical TAVR Because They Want TAVR

The NOTION 2 Low-risk Trial in Younger Patients

The Evolut R Low-risk Trial

The PARTNER 3 Low-risk Trial

Viewpoint #2: Not So Fast! GARY and Other Studies Indicate an Important Role for Surgery in Intermediate-risk Patients

Viewpoint #1: PARTNER 2A and SURTAVI are Convincing TAVR is Preferred in ALL (Appropriate) Intermediate-Risk Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content